In 1998, I was diagnosed with metastatic melanoma and given months to live. I consulted more than a dozen leading oncologists and got conflicting recommendations. No one could tell me: ‘Which treatment is best for me?’

A clinical trial saved my life—despite itself being unsuccessful—only raising more questions. Why did this therapy work for me but not for others? Could my experience help similar patients? It was life-saving knowledge I wanted to share with all cancer patients.

Welcome to Cancer Commons.

Marty Tenenbaum, PhD Founder of Cancer Commons

Since our founding in 2011, we have delivered personalized, evidence-based guidance at no charge to more than 10,000 patients and caregivers, supported entirely by philanthropy.

  • I had never reached out to anyone else besides my oncologist’s team. I was so shocked that I did not know about you. No one ever brought up trials with me. Cancer Commons was the first and only. The National Cancer Institute should be funding you. Everyone should have access to Cancer Commons.

    Michelle Kendall
    Cancer Patient

  • Whether via email or phone, I found the representative polite, professional, courteous, and knowledgeable. And I like that they reached out to my oncologist.

    Donald
    Pancreatic cancer patient

  • Cancer Commons is truly unique at rapidly matching patients with advanced cancer with the best precision therapy or clinical trial.

    E. David Crawford, MD
    Cancer Commons Advisor

  • My contact was prompt, professional, and kind. Cancer Commons helped me review my options going forward.

    Cancer patient

  • To me, Cancer Commons has not only been a great resource but I feel the people I’ve dealt with are my friends. They give me a great sense of comfort. My questions and concerns are always addressed very promptly. I would highly recommend Cancer Commons.

    Susan
    Wife of glioblastoma patient

Cancer Commons is staffed by accomplished researchers with PhDs in the molecular biology and pharmacology of cancer and in Artificial Intelligence. They have joined the Commons to apply their knowledge and expertise to help patients research their options in real time using the latest tools of precision oncology.